Development of [F-18]-Labeled Amyloid Imaging Agents for PET

Mathis, C. A.

University of Pittsburgh

关键词: Diseases;    Radiopharmaceuticals;    62 Radiology And Nuclear Medicine;    In Vivo;    Testing;   

DOI  :  10.2172/903085
RP-ID  :  DOE/ER/63590
RP-ID  :  FG02-03ER63590
RP-ID  :  903085

美国|英语

来源: UNT Digital Library

【 摘 要 】

The applicant proposes to design and synthesize a series of fluorine-18-labeled radiopharmaceuticals to be used as amyloid imaging agents for positron emission tomography (PET). The investigators will conduct comprehensive iterative in vitro and in vivo studies based upon well defined acceptance criteria in order to identify lead agents suitable for human studies. The long term goals are to apply the selected radiotracers as potential diagnostic agents of Alzheimer's disease (AD), as surrogate markers of amyloid in the brain to determine the efficacy of anti-amyloid therapeutic drugs, and as tools to help address basic scientific questions regarding the progression of the neuropathology of AD, such as testing the "amyloid cascade hypothesis" which holds that amyloid accumulation is the primary cause of AD.